Direct Buyers Push 1st Circ. To Rethink Nexium Suit
The direct purchasers of heartburn medication Nexium have asked the First Circuit to reconsider its November dismissal of a class action alleging AstraZeneca PLC paid generics maker Ranbaxy Inc. to delay...To view the full article, register now.
Already a subscriber? Click here to view full article